87 results about "Triple-Negative Breast Carcinoma" patented technology

This invention relates to the treatment of androgen receptor-positive breast cancer in a subject, for example a female subject. Accordingly, this invention provides methods of: a) treating a subject suffering from breast cancer; b) treating a subject suffering from metastatic breast cancer; c) treating a subject suffering from refractory breast cancer; d) treating a subject suffering from AR-positive breast cancer; e) treating a subject suffering from AR-positive refractory breast cancer; f) treating a subject suffering from AR-positive metastatic breast cancer; g) treating a subject suffering from AR-positive and ER-positive breast cancer; h) treating a subject suffering from triple negative breast cancer; i) treating a subject suffering from advanced breast cancer; j) treating a subject suffering from breast cancer that has failed SERM (tamoxifen, toremifene), aromatase inhibitor, trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), lapatinib, exemestane (Aromasin), bevacizumab (Avastin), and / or fulvestrant treatments; k) treating, preventing, suppressing or inhibiting metastasis in a subject suffering from breast cancer; l) prolonging survival of a subject with breast cancer, and / or m) prolonging the progression-free survival of a subject with breast cancer; comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound, comprising administering to the subject a therapeutically effective amount of a SARM compound of this invention.

Provided is a compound useful as a prophylactic and / or therapeutic agent for bladder cancer.As a result of studies on compounds having FGFR inhibitory action, the present inventors have found that the nitrogen-containing aromatic heterocyclic compounds of the present invention have inhibitory action on FGFR1, FGFR2, and / or FGFR3, particularly, mutant FGFR3, and thus, the present invention has been accomplished. The nitrogen-containing aromatic heterocyclic compound of the present invention can be used as a therapeutic agent for various cancers related to FGFR1, FGFR2, and / or FGFR3, such as lung cancer and hormone therapy-resistant breast cancer, stomach cancer, triple negative breast cancer, endometrial cancer, bladder cancer, and glioblastoma, particularly as a prophylactic and / or therapeutic agent for mutant FGFR3-positive bladder cancer.

The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an anti-Trop-2 antibody or antigen-binding antibody fragment. In preferred embodiments, the antibody may be an hRS7 antibody. The methods and compostions are of use to treat Trop-2 expressing cancers in human patients, preferably in patients who are resistant to or relapsed from at least one prior anti-cancer therapy, more preferably in patients who are resistant to or relapsed from treatment with irinotecan. The immunoconjugate may be administered at a dosage of 3 mg / kg to 18 mg / kg, preferably 8 to 12 mg / kg, more preferably 8 to 10 mg / kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size and reduce or eliminate metastases. Preferred tumors to treat with the subject immunoconjugates include triple-negative breast cancer, HER+, ER+, progesterone+ breast cancer, metastatic non-small-cell lung cancer, a metastatic small-cell lung cancer and metastatic pancreatic cancer.

The invention provides a furanocoumarin-Base derivative, wherein the structural formula of the derivative is as shown in the following formula 6 or 7; the derivative is synthesized by performing ringformation and coupling reaction on parabromoaniline,paraformaldehyde, 4-hydroxycoumarin, isonitrile and n-butyllithium; and the synthesis process is mild in reaction condition, short in reaction timeand high in yield. The Base derivative containing a coumarin fragment has excellent luminescent property and high bioactivity; some of the products have anti-tumor activity, show high-selectivity inhibition on human triple negative breast cancer cells (MDA-MB-231) and have research value of being further developed into anti-tumor medicines; and the other products can be applied to synchronous detection on neuroblastoma metabolites homovanillic acid (HVA) and vanilmandelic acid (VMA) and have the potential of being developed into a high-efficiency fluorescent probe for human neuroblastoma earlywarning and definite diagnosis.

The invention belongs to the technical field of biology and relates to an application of an SGCE gene as a triple negative breast cancer marker. According to the invention, high expression of SGCE intissues or cells of triple negative breast cancer is confirmed through biological information data processing and in vitro and in vivo experimental results, and survival analysis shows that the expression of the SGCE gene is closely related to the prognosis of the triple negative breast cancer, so that the SGCE gene can be used as a marker for diagnosis or prognosis evaluation of the triple negative breast cancer. The invention provides an application of a reagent or a kit for early screening, early diagnosis, early treatment and prognosis evaluation of the triple negative breast cancer, provides a strategy with great prospect for a patient with the triple negative breast cancer to be out of pain, and provides a good tool for basic research and clinical research of breast cancer and othercancers.

The invention provides a fluorescence labeled human triple-negative breast cancer osseous metastasis cell line. The fluorescence labeled human triple-negative breast cancer osseous metastasis cell line is prepared with a method as follows: a human triple-negative breast cancer cell MDA-MB-231 is cultured; a lentivirus carrier containing RFP (red fluorescence protein) is amplified, and an RFP labelled MDA-MB-231 cell is prepared; the RFP-MDA-MB-231 cell is transplanted to the fourth pair breast fat pad position of a nude mouse and grows into tumor; shin bone of a hind limb is taken after 4-6 weeks, bone marrow is flushed with a buffer solution and digested with collagenase, a single cell from the bone marrow is obtained, in-vitro culture amplification is performed, and red fluorescence cells are sorted with a flow cytometry; through tumor formation screening in a body of the nude mouse, the red fluorescence labelled MDA-MB-231 human triple-negative breast cancer osseous metastasis cellline is obtained. The human triple-negative breast cancer osseous metastasis cell line has the characteristics of osseous metastasis, is labelled by fluorescent protein and realizes visualization andtraceability.

The invention relates to a miR-506 targeting PENK gene of triple negative breast cancer cells and application of the miR-506. By screening miRWalk2.0, miRBase, TargetScanHuman 7.0 databases and detecting tissue samples of triple negative breast cancer patients by using a qRT-PCR technology, it is confirmed that the expression of miR-506 in the triple negative breast cancer is decreased significantly, and is averagely down-regulated by 88.95%, a dual-luciferase reporter experiment confirms that miR-506 can directly interact with Penk, and it is indicated that miR-506 can target PENK. Accordingto the miR-506 targeting the PENK gene of the triple negative breast cancer cells and the application of the miR-506, it is proved that miR-506 affects the proliferation, metastasis and invasion of triple negative breast cancer cells by increasing the content of penk in a targeting mode; the effectiveness of miR-506 targeting penk in inhibiting the progression of the triple negative breast canceris detected through a nude mouse breast cancer model; and the results show that the miR-506 can inhibit the development of the triple negative breast cancer through targeting penk.

In one aspect, the present disclosure provides a method of predicting disease progression comprising: (a) obtaining a sample of breast tissue that is estrogen receptor negative, progesterone receptor negative and does not over-express human epidermal growth factor 2 receptor protein; and (b) determining the expression of glia maturation factor beta, wherein expression of glia maturation factor beta is indicative of lymph node metastatis. In another aspect, the present disclosure provides a method of predicting disease progression comprising: (a) obtaining a sample of breast tissue that is estrogen receptor negative, progesterone receptor negative and does not over-express human epidermal growth factor 2 receptor protein; and (b) determining the expression of glia maturation factor beta, wherein expression of glia maturation factor beta is indicative of an untreated or treated prognosis that is reduced compared to an absence of the expression.

The invention discloses an EGFR (epidermal growth factor receptor)-specific chimeric antigen receptor and application thereof. The EGFR-specific chimeric antigen receptor comprises a transmembrane signal region, an extracellular recognition region, a hinge region, a transmembrane region and an intracellular signal transduction region, which are connected in sequence. A CAR-T with the surface modified by the EGFR-specific chimeric antigen receptor has a strong tumor-specific antigen activation effect, a cytokine secretion function and a tumor-killing ability for triple negative breast cancer; the in-vitro killing efficiency is more than 90% under a low effector-to-target ratio; animal experiments verify the remarkable effective inhibitory effect of the CAR-T, the CAR-T has a remarkable tumor suppressive effect in in-vivo experiments, and accordingly, it is indicated that the CAR-T of the EGFR-specific chimeric antigen receptor has high applicability to the triple negative breast cancer.

The invention discloses a monoclonal antibody for treating triple-negative breast cancer and application thereof for breast cancer treatment. Particularly, the monoclonal antibody provided by the invention has one or a plurality of characteristics as follows: (a) the monoclonal antibody specially inhibits the combination of protein C and protein C receptors (PROCR); (b) the monoclonal antibody is combined with the protein C receptors, and in addition, a combination region is a region generating combination with the protein C on the protein C receptors (PROCR); (c) the monoclonal antibody is (i) a monoclonal antibody RCR-252 or (ii) a competitive antibody of the RCR-252. The monoclonal antibody disclosed by the invention has the advantages that the growth of the breast cancer cells (particularly the triple-negative breast cancer cells) can be obviously inhibited, so that the monoclonal antibody can be used as a potential treatment agent for the breast cancer (particularly the triple-negative breast cancer).

The invention provides a molecular biomarker for diagnosing and treating triple-negative breast cancer and application thereof, and belongs to the technical field of crude drugs and molecular biology.The invention finds for the first time that circEIF3H expression in a tumor specimen of a patient suffering from triple-negative breast cancer is obviously higher than that of breast cancer tissues of other subtypes, meanwhile, the circEIF3H expression quantity is related to prognosis of triple-negative breast cancer, and malignant growth and invasion capacity of breast cancer cells can be controlled by regulating the circEIF3H expression. Therefore, the circEIF3H can be used as a molecular biomarker for diagnosing and treating the triple-negative breast cancer, and can be used as a prognosisindex and a potential treatment target of the triple-negative breast cancer. The biomarker provides a more favorable means for diagnosis and prognosis evaluation analysis of the triple-negative breast cancer, has important significance for research and treatment of the triple-negative breast cancer, and thus, has favorable practical application value.

The invention provides application of combination of 5-fluorouracil and paclitaxel in preparation of a medicine for treating breast cancer, and belongs to the field of pharmacy. The invention particularly provides a pharmaceutical composition for treating breast cancer. The composition is a preparation prepared by taking 5-fluorouracil and paclitaxel as active ingredients and adding a pharmaceutically acceptable carrier, wherein the mass ratio of the 5-fluorouracil to the paclitaxel is (2-4):2. According to the invention, it is found for the first time that when 5-fluorouracil and paclitaxel are combined in a specific ratio, the inhibition effect on triple negative breast cancer cells has a synergistic effect. Experimental results show that compared with a free drug and an unmodified double-drug-loading liposome which are used in a combined manner, the polypeptide modified double-drug-loading liposome provided by the invention has a remarkably improved in-vivo anti-tumor effect; and moreover, while the anti-tumor effect is improved, the polypeptide modified double-drug-loading liposome provided by the invention also reduces the systemic toxicity, improves the safety of tumor treatment, and has a wide application prospect.

The invention discloses an application of a compound (E)-N-(4-methoxy benzylidene)-1-(3-(6-chloropyridine)methyl)-3-(4-chlorphenyl)-1H-pyrazole-5-carbohydrazide in preparation of an anti-breast cancer drug, wherein the breast cancer is triple-negative breast cancer specifically. Experiments verify that the compound has an obvious effect in inhibition of MDA-MB-231 breast cancer cell proliferation and induction of apoptosis, an anti-tumour test effect is good and no toxic or side effect is produced, so that the compound has a good development application prospect in preparation of the anti-breast cancer drug and can become an effective anti-cancer drug for the triple-negative breast cancer with less optional drugs at present.

The invention discloses base-Schiff base derivatives. A structural general formula of the base-Schiff base derivatives is as shown in a formula [I] as shown in the specification, and the base-Schiff base derivatives are produced by subjecting raw materials of p-bromoaniline, paraformaldehyde, n-butyllithium, p-aminobenzoic acid, substituted o-phenylenediamine and the like to a condensation reaction. The base-Schiff base derivatives fluoresce, emit blue light, and have obvious aggregation-induced emission and solid-state emission, part of compounds have capability of recognizing Al3+, and two compounds have good effects of inhibiting one or two kinds of triple-negative breast cancer cells and liver caner cells, and have small toxicity to normal cells; and three compounds have certain degrees of effects of inhibiting one or more kinds of non-small cell lung cancer cells, triple-negative breast cancer cells and liver cancer cells.

The structural general formula of the novel Base-imidazole derivative is shown as any one of the following formulas, and the novel Base-imidazole derivative is prepared from p-bromoaniline, paraformaldehyde, n-butyllithium, phenanthrenequinone / biphenyl formyl / acenaphthenequinone and substituted aniline through cyclization and coupling reaction. The novel Base-imidazole derivative provided by the invention emits blue light, has obvious aggregation-induced emission and solid-state emission, has good thermal stability, meets the basic requirements of device materials, and has certain applicationpotential. Part of the novel Base-imidazole derivatives have a good inhibition effect on one or two of triple-negative breast cancer cells and liver cancer cells, and have low toxicity to normal cells; part of the novel Base-imidazole derivatives can inhibit one or more of non-small cell lung cancer cells, triple negative breast cancer cells and lung cancer cells to a certain extent.

The invention relates to CD146 and antibody diagnosis thereof, and an application thereof in treating triple negative breast cancers. For a first time, the invention provides that CD146 is a novel target of triple negative breast cancer, and an anti-CD146 antibody might become a novel targeting medicine for treating the disease. Therefore, the invention provides an application of CD146 or anti-CD146 antibody or a functional form of the antibody in preparing medicines used for diagnosing and / or treating triple negative breast cancers. CD146 molecules are subjected to specific high expression in triple negative breast cancer tissues, and induce the occurrences of transformation of epithelial cell to mesenchymal cell in tumor cells. Therefore, tumor invasion migration is promoted. Therefore, the mechanism for CD146 antibody to treat triple negative breast cancer is mainly that the CD146 antibody inhibits the mesenchymal cell characteristics of triple negative breast cancer, and reduces the metastasis invasion capacity thereof. Compared with common chemotherapy medicines, the anti-CD146 antibody has the advantages of low side effects and clear target. The anti-CD146 antibody does not cause whole-body side effect.

The present invention provides an application of a compound for targeted inhibition of CDK7 in preparation of inhibited triple negative breast cancer stem cells. The compound for targeted inhibition of CDK7 is THZ1. The CDK7 targeting inhibitor THZ1 can specifically inhibit growth and stemness maintenance of the triple negative breast cancer stem cells and in-vivo tumorigenesis and growth of the stem cells. Transcriptome sequencing and subsequent biochemical experiment verifications show that the CDK7-targeting inhibitor THZ1 can specifically regulate and control a tumor stemness Notch-Hes signaling pathway, promote stemness transformation of triple-negative breast cancer stem cell subsets, transform stemness cell subsets into non-stemness cells, cause cycle arrest of the triple-negative breast cancer stem cells, inhibit DNA damage repair, promote cell apoptosis, meanwhile, can also directly cause the apoptosis of the stem cells, can remarkably influence growth of the triple-negative breast cancer stem cells, and meanwhile, can play a synergistic sensibilization function in the radiotherapy of the triple-negative breast cancer stem cells.

The invention discloses a pharmaceutical composition for treating a triple negative breast cancer and application thereof. The pharmaceutical composition is prepared from thiazolidinedione and hydralazine. Application of the pharmaceutical composition in preparation of a medicament for treating a disease of the triple negative breast cancer, application of preparation in the medicament for improving PPAPgama protein and PPAPgammanRNA expression in triple negative breast cancer cell, application in preparation of the medicament for restraining cell multiplication of the triple negative breast cancer, and application in preparation of the medicament for promoting cell apoptosis of the triple negative breast cancer are also provided by the invention. A new way of thinking is brought about for treatment of a sufferer with the triple negative breast cancer by the pharmaceutical composition and the application thereof provided by the invention; and a new application field of the pharmaceutical composition is developed.

The invention relates to application of a reagent for knocking down RBMS1 in preparation of a medicine for treating triple negative breast cancer, and belongs to the technical field of anti-tumor medicines. The invention provides application of a reagent for knocking down RBMS1 in preparation of a medicine for treating triple negative breast cancer. The knock-down of the RBMS1 gene in the triple negative breast cancer can inhibit B4GALT1 gene transcription and then down-regulate PD-L1 expression so as to influence the ability of infiltrating lymphocytes in tumors to kill tumor cells, enhance the sensitivity of triple negative breast cancer immunotherapy and provide a new potential target for triple negative breast cancer immunotyping and treatment.

The invention relates to the technical field of medicines, in particular to an application of Cynanoside H in preparation of a drug for preventing and treating a breast cancer. A pharmacological studyshows that Cynanoside H inhibits MDA-MB-231 cell proliferation through inducing S-phase cycle arrest, reverses epithelial-mesenchymal transition to inhibit MDA-MB-231 cell migration and invasion, plays a role in preventing and treating the breast cancer, especially triple-negative breast cancer, and provides a new idea for research and development of the drug for preventing and / or treating the breast cancer.

The invention relates to a physical method for selectively containing the malignant degree of triple negative breast cancer cells. The physical method is characterized in that firstly, low-temperature normal-pressure helium plasmas are utilized to treat a culture medium to activate the culture medium, so that the culture medium carries with a large number of effective active substances; and then the breast cancer cells can be killed by means of the method that the active substances interact with the breast cancer cells through the treated culture medium, so that the effect on containing of the malignant degree of the triple negative breast cancer cells is achieved. According to the physical method for selectively containing the malignant degree of the triple negative breast cancer cells, the low-temperature normal-pressure helium plasmas are adopted so that the culture medium can generate the appropriate active oxygen substances, the containing effect on the triple negative breast cancer cells is achieved, and nearly no influence on normal cells is generated, so that high selectivity is achieved; and the breast cancer cells are treated through the indirect physical method, the convenient and efficient characteristics are achieved, and a culture medium solution subjected to plasma treatment can be treated as medical injection liquid to conduct injection therapy on breast cancer patients. According to the physical method, the triple negative breast cancer cells are safely, painlessly and efficiently killed without side effects.

The invention belongs to the technical field of nano-medicaments, and discloses a hypoxia response chiral medicament micelle for targeting triple-negative breast cancer and a preparation method of thehypoxia response chiral medicament micelle. The preparation method comprises the following steps: firstly, introducing an azobenzene group into a molecular chain of carboxyl polyethylene glycol active ester, and obtaining carboxyl polyethylene glycol azobenzene; then, preparing the carboxyl polyethylene glycol-azobenzene-dextrorotatory polylactic acid segmented copolymer through reaction with carboxyl dextrorotatory polylactic acid; then introducing an amino-modified aptamer AS1411 to prepare AS1411-modified polyethylene glycol-azobenzene-dextral polylactic acid, compounding a fat-soluble anti-cancer drug, and then dialyzing to obtain the micelle disclosed by the invention. The low-oxygen-response chiral medicament micelle provided by the invention is small in particle size and narrow indistribution, and can be effectively retained at a targeted part; low-oxygen responsiveness is achieved, and the effect of low-oxygen slow release is achieved; TNBC tumors can be targeted, anti-cancerdrugs are selectively released, and the anti-tumor effect is remarkably improved.

The invention relates to a nano drug delivery system for co-encapsulating siRNA and a hydrophobic drug, and a preparation method and application thereof. According to the invention, nanoparticles co-encapsulating the hydrophobic drug and the siRNA are prepared by coupling hydroxyethyl starch and cholesterol with good biocompatibility, and the nanoparticles have pH-sensitive FX drug release capability, are uniform in particle size, stable in structure and good in biocompatibility, have the characteristics of multiple drug loading types and high stability when being compared with common nano carriers such as liposomes and micelles, can effectively deliver FX and the siRNA to the breast cancer site in a targeting mode so as to inhibit the growth of the breast cancer, and can inhibit the metastasis of the breast cancer and achieve the effect of the FX and the siRNA synergistic treatment on the triple negative breast cancer.

The invention discloses a method for constructing a model of treating triple negative breast cancer with ulinastatin. The method for constructing the model comprises the following steps: constructing a TNBC (triple negative breast cancer) cell model of CCL22 over-expression and knockdown; constructing a mice tumor-bearing model by virtue of 4T1 cells of CCL22 over-expression and knockdown; and constructing a mice transplantation tumor model by virtue of the 4T1 cells. Meanwhile, the invention discloses a method for detecting influence and mechanism of the ulinastatin on treating the triple negative breast cancer, wherein the method comprises the following steps: detecting inhibition of the ulinastatin on the amount of chemotactic factors CCL22 secreted by TNBC cells; detecting recruitment of the CCL22 on treg cells around the tumor cells; and detecting the expression of GITR on the surface of the treg cells. The research of the invention on the therapeutic value of the ulinastatin on treating the breast cancer is the first case at home and abroad; and the research on the mechanism of the drug affecting tumor microenvironment can offer an application basic research for the clinical application of the drug in the treatment of the breast cancer, in particular the treatment of the triple negative breast cancer.

The invention discloses a marker for detecting triple negative breast cancer as well as a detection reagent and application thereof, and relates to the technical field of tumor detection. By detecting the expression level of at least one marker of ZEB1-AS1, TMEM254-AS1, LINC01087, LINC01122 and LINC00856 and utilizing differentiated expression of the markers in triple negative breast cancer tissue and para-carcinoma tissue of the triple negative breast cancer tissue, the marker can be used for diagnosis, prognosis evaluation or drug screening of the triple negative breast cancer.

The invention provides a liposome co-loaded with CD73 antibody and adriamycin, and a preparation method and application of the liposome. A lipid core coated with the adriamycin is arranged in the liposome co-loaded with the CD73 antibody and the adriamycin, the outside of the lipid core is modified with the CD73 antibody, and the CD73 antibody is coupled to a phospholipid PEG active ester micelle and then is modified on the surface of the lipid core. The lipidosome co-loaded with the CD73 antibody and the adriamycin reduces the drug resistance and the toxic and side effects of the adriamycin in treatment of the triple negative breast cancer, improves in-vivo biological distribution of the adriamycin, improves bioavailability, and turns an immune microenvironment in a triple negative breast cancer tumor, so that the triple negative breast cancer tumor is converted into a thermal tumor, and a relatively good treatment effect for the triple negative breast cancer is realized.

The invention discloses a molecular structure and a synthesis method of a new triple negative breast cancer drug. The molecular structure is pHLIP (Var7)-P1AP, wherein pHLIP (Var7)-AEEQNPWARYLEWLFPTETLLLELC and P1AP-CKKSRALF are synthesized by the steps of 1) synthesizing a pHLIP (Var7) Cys polypeptide sequence through a solid-phase polypeptide synthesis method: AEEQNPWARYLEWLFPTETLLLELC; 2) synthesizing a Cys P1AP polypeptide sequence through a solid-phase polypeptide synthesis method: CKKSRALF; and 3) enabling the pHLIP (Var7) Cys to be connected with the Cys P1AP through a disulfide bond toobtain the pHLIP (Var7)-P1AP sequence: AEEQNPWARYLEWLFPTETLLLELC-CKKSRALF. The C end of the pHLIP (Var7)-P1AP can be specifically inserted into triple negative breast cancer cells, the disulfide bondcracks to release P1AP to tumor cells, and P1AP can be targeted to the internal parts of tumor cell PAR1 recipient cells to achieve the purpose of inhibiting tumor cell proliferation.

The invention discloses an artificially synthesized anticancer peptide and an acid responsive nanoparticle precursor thereof. The nanoparticle is formed by connecting an anti-cancer peptide and an amphiphilic monomethyl polyethylene glycol-polypropylene glycol polymer through an acid-responsive chemical bond. Tests prove that the anti-cancer peptide can kill tumor cells through membrane rupture activity, and has the advantages of excellent broad-spectrum anti-cancer activity and drug resistance. The nanoparticles are selectively sensitive to a tumor subacid environment, can completely release anti-cancer peptides, and play an active role of a targeted tumor cell line. And the polypeptide has the advantages of hemolysis resistance, high plasma stability, low in-vivo systemic toxicity, systemic drug delivery and the like. The nanoparticle has a remarkable inhibition effect on various tumor cells including triple negative breast cancer, and particularly has a relatively good clinical application potential on drug-resistant triple negative breast cancer.

The invention belongs to the technical field of biology, and relates to application of a reagent for inhibiting an SGCE gene and a tumor chemotherapy drug to preparation of a drug for treating tumor chemotherapy and application of a reagent for inhibiting the SGCE gene to preparation of a drug for treating EGFR high-expression tumor. It is found that enrichment of tumor stem cells caused by chemotherapeutic drugs can be weakened after the SGCE gene is inhibited; after the SGCE is inhibited, the combination of the Cbl and the EGFR is enhanced; egfr degradation, finally, the sensitivity of the EGFR inhibitor-resistant cell strain to the EGFR inhibitor is remarkably enhanced, and it is prompted that the drug resistance of tumor cells to the EGFR inhibitor can be overcome when the inhibitor for synthesizing the SGCE and the EGFR inhibitor are jointly applied to drugs for treating EGFR high-expression tumors. Therefore, proliferation and metastatic growth of various EGFR high-expression tumors such as triple-negative breast cancer, non-small cell lung cancer, colorectal cancer and the like can be effectively inhibited by jointly inhibiting EGFR while inhibiting SGCE, and recurrence of cancer is effectively prevented. The reagent has important guiding significance in clinical application and has a wide prospect.